0001790300-21-000010.txt : 20210917
0001790300-21-000010.hdr.sgml : 20210917
20210917185157
ACCESSION NUMBER: 0001790300-21-000010
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210722
FILED AS OF DATE: 20210917
DATE AS OF CHANGE: 20210917
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STANKOVICH THOMAS
CENTRAL INDEX KEY: 0001181166
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37897
FILM NUMBER: 211261682
MAIL ADDRESS:
STREET 1: 1001 CALLE AMANECER
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92673
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ReShape Lifesciences Inc.
CENTRAL INDEX KEY: 0001427570
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1001 CALLE AMANECER
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92673
BUSINESS PHONE: 949-429-6680
MAIL ADDRESS:
STREET 1: 1001 CALLE AMANECER
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92673
FORMER COMPANY:
FORMER CONFORMED NAME: OBALON THERAPEUTICS INC
DATE OF NAME CHANGE: 20080220
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2021-07-22
0
0001427570
ReShape Lifesciences Inc.
RSLS
0001181166
STANKOVICH THOMAS
1001 CALLE AMANECER
SAN CLEMENTE
CA
92673
0
1
0
0
Chief Financial Officer
Common Stock, $0.001 par value per share
2021-07-22
4
A
0
282382
0
A
315995
D
Common Stock, $0.001 par value per share
2021-07-22
4
A
0
90362
0
A
406357
D
Common Stock, $0.001 par value per share
2021-09-10
4
S
0
48366
2.89
D
357991
D
These shares will vest and be issued with respect to 123,542 shares on July 22, 2021 and the remaining shares vesting monthly thereafter for 36 months pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
These shares will vest and be issued monthly over 36 months beginning on July 22, 2021 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
These shares were sold to cover taxes in connection with the vesting of restricted stock units.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.88 to $2.90, inclusive. The Reporting Person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
/s/Thomas Stankovich
2021-09-17